Syneos Health Buys Leading CRO Synteract
Is the market for contract research organizations on the rise again? After a slow year for CRO transactions, the new deal by Syneos Health, Inc. (NASDAQ: SYNH) might signal a new turn in direction. Syneos Health, a fully-integrated biopharmaceutical solutions organization, announced last week it was acquiring Synteract Inc. from Amulet Capital Partners for $400 million. Synteract is a leading CRO that supports biotech and pharma companies across all phases of drug development. Synteract’s 700 employees across North America, Europe, Asia Pacific and Africa have supported more than 4,000 Phase 1-4 clinical trials across 26,000 sites in more than 60 countries. Amulet acquired Synteract in May... Read More »
CRO M&A Market in 2020 (So Far)
There haven’t been many deals targeting contract research organizations (CRO) in 2020, especially compared to previous years, which makes sense. Life science companies are all slowing down clinical trials (COVID-19 vaccine research excluded) to adhere to social distancing guidelines, meaning CRO services are just not in as high demand. For 2020, only 10% of deals in the Other Services sector have targeted a CRO company (14 deals). To put that in context, CROs were targeted in 15% (29 transactions) of deals in the Other Services sector for 2019, according to The 2020 Health Care Services Acquisition Report. There haven’t been many headline deals this year for the CRO market.... Read More »
Catalent acquires MaSTherCell Global
Catalent, Inc. (NYSE: CTLT) announced a $315 million deal for MaSTherCell Global, a technology-focused cell and gene therapy contract development and manufacturing organization based in Gosselies, Belgium. It is backed by Great Point Partners, SFPI-FPIM (the Belgian Federal Holdings and Investment Company) and Orgenesis Inc. (NASDAQ: ORGS). This is the Somerset, New Jersey-based CRO’s fifth deal since 2014, all of them for domestic targets, according to search results in our Healthcare Deals Database. Its most recent one was announced in April 2019, for Baltimore-based Paragon Bioservices, Inc., a contract research organization, for $1.2 billion. Founded in 2011, MaSTherCell has a... Read More »
PE Firms Trade WIRB-Copernicus for $3 Billion
Leonard Green & Partners, L.P won the auction to acquire WIRB-Copernicus Group (WCG) from Arsenal Capital Partners for $3 billion. The purchase value was originally reported in PE Hub Buyouts. WCG is a clinical services organization that enables biopharmaceutical companies, contract research organizations and institutions to accelerate the delivery of new treatments and therapies to patients. Arsenal will retain a stake in WCG. It acquired the company in March 2012 and led its recapitalization in August 2016 alongside other investors, including MSD Partners, the family office of Michael Dell. WCG has an estimated EBITDA of $175 million for 2019. WCG has been relatively quiet on the... Read More »